Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.59 |
| ▸ | EGFR | P00533 | 4/20 | 0.51 |
| ▸ | AR | P10275 | 6/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.47 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22661301 | 0.89 | CRBN (0.58) | CRBNEGFRARHPGDSDDB1 | |
| SCHEMBL31752835 | 0.88 | CRBN (0.60) | CRBNARHPGDSDDB1BTK | |
| SCHEMBL20305748 | 0.87 | CRBN (0.62) | CRBNEGFRARHPGDSDDB1 | |
| Hydrochloric Acid SCHEMBL20359641 | 0.87 | CRBN (0.61) | CRBNEGFRARHPGDSDDB1 | |
| SCHEMBL29596434 | 0.86 | CRBN (0.60) | CRBNARHPGDSDDB1BTK | |
| SCHEMBL23639844 | 0.86 | CRBN (0.55) | CRBNEGFRARHPGDSDDB1 | |
| SCHEMBL23143032 | 0.85 | CRBN (0.55) | CRBNEGFRARHPGDSDDB1 | |
| SCHEMBL29856011 | 0.85 | CRBN (0.47) | CRBNEGFRDDB1HRH3LRRK2 | |
| SCHEMBL22906898 | 0.85 | CRBN (0.65) | CRBNEGFRDDB1BRD9ERBB2 | |
| SCHEMBL20305725 | 0.84 | CRBN (0.54) | CRBNEGFRARHPGDSDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135173-A1 | NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135173-A1 | NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, NR5A1, ESRRA | CRBN 409/4885EGFR 280/4885AR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.